Treatment of refractory AML

Leukemia

Volumn 10, Issue 6, 1996, Pages 932-936

  Estey, E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bayesian designs; Prognosis of relapsed AML

Indexed keywords

AMSACRINE; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; HUMAN; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT PLANNING;

EID: 0030018203     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (19)

1. Davis CL, Rohatiner AZS, Lim J, Whelan JS, Oza AM, Amess J, Love S, Stead E, Lister TA. The management of recurrent acute myelogenous leukemia at a single centre over a fifteen-year period. Br J Haematol 1993; 83: 404-411.
2. Angelov L, Brandwein JM, Baker MA, Scott JG, Sutton DM, Keating A. Results of therapy for acute myeloid leukemia in first relapse. Leuk Lymphoma 1991; 6: 15-24.
3. Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, Beran M, McCredie KB, Freireich EJ. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 1989; 7: 1071-1080.
4. Hiddemann W, Martin WR, Sauerland CM, Heinecke A, Buchner T. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 1990; 4: 184-188.
5. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985; 69: 1375-1381.
6. Thall P, Estey E. A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation. Stat Med 1993; 12: 1197-1211.
7. Gehan E. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961; 13: 346-353.
8. Santana VM, Mirro J Jr, Kearns C, Schell MJ, Crom W, Blakely RL. 2-chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 1992; 10: 364-370.
9. Vahdat L, Wong ET, Wile MJ, Rosenblum M, Foley KM, Warrell RP Jr. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood 1994; 84: 3429-3434.
10. Kornblau S, Andreeff M, Beran M, Escudier S, Kantarjian H, Koller C, O'Brien S, Robertson LE, Estey E. 2-CDA ± ARA-C is ineffective therapy for relapsed or refractory AML in adults. Proc Am Soc Clin Oncol 1995; 14: 336.
11. O'Brien S, Kantarjian H, Estey E, Koller C, Beran M, McCredie K, Keating M. Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia. Cancer 1991; 68: 691-694.
12. Ho AD, Lipp T, Ehninger G, Illiger HJ, Meyer P, Freund M, Hunstein W. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia - an active and well-tolerated regimen. J Clin Oncol 1988; 6; 213-217.
13. Lazzarino M, Morra E, Alessandrino EP, Orlandi E, Pagnucco G, Merante S, Bernasconi P, Inverardi D, Bonfichi M, Bernasconi C. Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia. Eur J Haematol 1989; 43: 411-416.
14. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher V, Baier M, Dalton W. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993; 11: 1652-1660.
15. Carella AM, Carlier P, Pungolino E, Resegotti L, Liso V, Stasi R, Montillo M, Iacopino P, Mirto S, Pagano L, Leoni F, Martelli FM, Raimondo FD, Porcellini A, de Riu L, Nosari AM, Cimino R, Damasio E, Miraglia E, Fioritoni G, Ricciuti F, Carotenuto M, Longinotti M, Defazio D, Fazi P, Mandelli F for the GIMEMA Cooperative Group. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. Leukemia 1993; 7: 196-199.
16. Biggs JC, Horowitz MM, Gale RP, Ash RC, Atkinson K, Helbig W, Jacobsen N, Phillips GL, Rimm AA, Ringdén O, Rozman C, Sobocinski KA, Veum JA, Bortin MM. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992; 80: 1090-1093.
17. Forman SJ, Schmidt GM, Nademanee AP, Amylon MD, Chao NJ, Fahey JL, Konrad PN, Margolin KA, Niland JC, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Somlo G, Stein AS, Blume KG. Allogeneic bone marrow transplantation as therapy for primary induction failure tor patients with acute leukemia. J Clin Oncol 1991; 9: 1570-1574.
18. Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating MJ, Estey EH. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 1993; 81: 1146-1151.
19. Gehan E. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961; 13: 346-353.